Key takeaways
- Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, also called TP-7; its first four amino acids are the sequence of tuftsin.
- Of 68 PubMed records on Selank, 64 come from Russian journals or research groups, and 42 mention rats or mice.
- We found five small human studies, all sharing one author, and none registered on ClinicalTrials.gov; only one abstract describes a placebo group.
- It is not FDA-approved. FDA lists selank acetate among substances whose Category 2 nominations were withdrawn, and says it lacks important safety information for people.
- It is not named in Australia’s Poisons Standard or on WADA’s 2026 and 2027 Lists, and neither absence means it is approved or permitted; its Russian and UK status could not be confirmed from primary records.
01Selank at a glance
The short version, dated 18 November 2026.
| Question | Selank |
|---|---|
| What it is | A peptide of seven amino acids, Thr-Lys-Pro-Arg-Pro-Gly-Pro. Formula C33H57N11O9, molecular weight 751.9 g/mol. Its first four amino acids are the sequence of tuftsin. |
| Other names | TP-7. FDA’s compounding page lists it as “Selank acetate (TP-7)”. |
| Evidence tier | Mostly T3 (rats, mice) and T4 (cells). In people: five small studies from Russian research groups, graded T2 here because their abstracts do not describe how participants were assigned; PubMed indexes two of them as randomised trials. |
| Registered trials | None on ClinicalTrials.gov (searched 18 Nov 2026). |
| United States | Not FDA-approved: no product in Drugs@FDA. Listed by FDA among substances previously in compounding Category 2 whose nominations were withdrawn. Not on FDA’s July 2026 advisory committee agenda, and not one of the six peptides in HHS’s October 2026 enforcement-discretion policy. |
| United Kingdom | Not confirmed from a primary record (see below). |
| Australia | Not named in the Poisons Standard October 2026. The TGA’s April 2026 advisory covers unapproved peptide products in general; its examples do not include Selank. |
| Russia | Not confirmed: we could not reach the Russian state register of medicines. |
| WADA | Not named on the 2026 or the 2027 Prohibited List; whether class S0 applies is unresolved (see below). |
02What is Selank?
Selank is a short peptide of seven amino acids: threonine, lysine, proline, arginine, proline, glycine and proline. The first four are the sequence of tuftsin, a four-amino-acid peptide, and Russian research papers describe Selank as a tuftsin analogue. PubChem lists TP-7 as a synonym and gives its CAS number as 129954-34-3.
Its research is almost entirely Russian. Of the 68 PubMed records with Selank in the title or abstract (18 November 2026), 64 are from Russian journals or Russian research groups; the other four are reviews or a laboratory analysis of seized products. A 2021 review in the Journal of Clinical Pharmacology, by US pharmacy researchers, called phenibut and Selank “poorly studied Russian drugs” that are sold to US consumers as dietary supplements.
Selank is not the same molecule as Semax, another seven-amino-acid peptide, and their US status differs: see Semax and Selank research.
03How has Selank been studied, and in what models?
Mostly in rats and mice: 42 of the 68 PubMed records mention them in the title or abstract. Here is the evidence by model, with what each study measured. Animal and cell findings are not evidence of an effect in people.
| Model | Examples | What was measured | Tier |
|---|---|---|---|
| Cells and tissue | Rat brain membranes (2018); human neuroblastoma IMR-32 cells (2017); mouse embryonic stem cells (2017) | Binding at GABA receptor sites; expression of 84 genes of the GABA system; cell growth, survival and differentiation, as a toxicity model | T4 |
| Rats and mice | Rats under unpredictable chronic mild stress, given Selank alone or with diazepam (2017); rat frontal cortex (2016); rats in a morphine-withdrawal model (2022) | Behaviour on the elevated plus maze; expression of 84 neurotransmission genes; signs of withdrawal | T3 |
| Monkeys | One Russian-language study (2008); the abstract gives no group sizes | Behaviour in a neurosis model | T3 |
| People | Five small studies, 2008 to 2020 | See the next section | T2 |
The mechanism these laboratories propose involves the brain’s GABA-A receptor system. In rat brain membranes, Selank changed how GABA bound to its receptors (2018). In human neuroblastoma cells, Selank on its own did not change the expression of 84 GABA-system genes (2017). Both are cell findings, not evidence about people.
04What human studies of Selank exist?
We found five studies in PubMed that gave Selank to people (18 November 2026). None is registered on ClinicalTrials.gov.
| Study | Design | People | What was measured |
|---|---|---|---|
| Zozulia et al., 2008 | Compared with medazepam, a benzodiazepine. PubMed indexes it as a randomised controlled trial; the abstract does not describe randomisation or blinding | 62 adults with generalised anxiety disorder or neurasthenia (30 Selank, 32 medazepam) | Rating scales (Hamilton, Zung, CGI); a blood measure of enkephalin breakdown |
| Uchakina et al., 2008 | Blood tests in patients given Selank for 14 days, with no comparison group described; plus laboratory tests on blood cells from patients with depression and from healthy controls | Patients with generalised anxiety disorder or neurasthenia; numbers not given in the abstract | Blood cytokine levels |
| Medvedev et al., 2014 | Compared with phenazepam, a benzodiazepine | 60 patients with anxiety-phobic and somatoform disorders | Anxiety ratings, tolerability, quality of life |
| Medvedev et al., 2015 | Phenazepam alone against phenazepam plus Selank. PubMed indexes it as a randomised controlled trial; the abstract does not describe blinding | 70 patients (30 and 40) with anxiety-spectrum disorders | Rating scales (HDRS, CGI, Spielberger); side effects (UKU scale); Stroop and verbal-fluency tests; quality of life (SF-36) |
| Panikratova et al., 2020 | Compared with Semax and with placebo | 52 healthy participants | Resting-state brain connectivity on fMRI, before and twice in the 20 minutes after |
Three cautions. Four of the five appeared in the same Russian-language psychiatry journal, and all five list the same author, N. F. Myasoedov (indexed as Miasoedov in older records), whose listed affiliations include the Institute of Molecular Genetics of the Russian Academy of Sciences. Only one abstract describes a placebo group. And we found no human study of Selank from any other group.
This page reports how the studies were designed, not what their authors concluded: with designs this thinly described and no independent repeat, the conclusions cannot be weighed. How we grade evidence: evidence grades.
05Is Selank an approved medicine? Status by country
United States. Selank is not an FDA-approved drug: Drugs@FDA lists no product containing it (openFDA, 18 November 2026). FDA’s compounding page lists “Selank acetate (TP-7)” among bulk substances previously in Category 2 whose nominations were withdrawn by the nominators. Its entry says compounded drugs containing it “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities”, and that FDA “lacks important information regarding any safety issues raised by selank acetate administered to humans”. The page gives no withdrawal date. Selank was not on the agenda of FDA’s compounding advisory committee in July 2026, and it is not one of the six peptides in HHS’s October 2026 enforcement-discretion policy. Background: FDA’s peptide categories.
United Kingdom. We could not confirm Selank’s UK status from a primary record: the MHRA’s medicines database did not return results our tools could read. How UK medicines law treats peptides: are peptides legal in the UK?
Australia. Selank is not named in the Poisons Standard October 2026, in force from 1 October 2026. The TGA’s April 2026 advisory covers unapproved peptide products in general, and its examples do not include Selank. Scheduling is not approval: the TGA calls a product approved when it is on the Australian Register of Therapeutic Goods, which we could not search because tga.gov.au did not respond. More: are peptides legal in Australia?
Russia. The 2021 US review above calls Selank a Russian drug. We could not confirm a registration at the primary source: the Russian state register of medicines (grls.rosminzdrav.ru) refused connections on 18 November 2026, and the Internet Archive holds only redirects for it. We state no Russian status until we can read it.
Sport. Selank is not named on WADA’s 2026 Prohibited List or on the 2027 List, in force from 1 January 2027. Class S0 covers any pharmacological substance not addressed elsewhere on the List “and with no current approval by any governmental regulatory health authority for human therapeutic use”, prohibited at all times; the 2027 List adds “peptides” to its examples. Whether S0 reaches Selank depends on an approval status we could not verify, and anti-doping organisations decide. See peptides and anti-doping.
06What we don’t know about Selank
- Any effect in people from a registered, placebo-controlled trial. We found none on ClinicalTrials.gov, and only one of the five published abstracts describes a placebo group.
- Replication. We found no human study of Selank from a group other than the research groups described above (PubMed, 18 November 2026).
- Its safety over months or years. FDA says it “lacks important information regarding any safety issues raised by selank acetate administered to humans”.
- Its status in Russia and the UK, which we could not confirm from primary records.
- What a vial sold as Selank contains. Only that lot’s lab report can show it: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.